Analyst Rating Update on TESARO (TSRO)

TESARO (NASDAQ:TSRO) : The consensus on TESARO (NASDAQ:TSRO) based on 8 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

TESARO (NASDAQ:TSRO) : The highest level TESARO (NASDAQ:TSRO) is projected to reach is $72 for the short term and the lowest estimate is at $53. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $61.86 and the possibility the share price can swing is $6.18.

For this week, the average consensus of the company shares are rated as a Strong Buy. Also, Credit Suisse initiates coverage on TESARO (NASDAQ:TSRO). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Credit Suisse announces a current price target of $56 per share. The rating by the firm was issued on May 13, 2016.

TESARO (NASDAQ:TSRO): On Tuesdays trading session , Opening price of the stock was $41.08 with an intraday high of $41.8899. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $36.71. However, the stock managed to close at $37.21, a loss of 8.37% for the day. On the previous day, the stock had closed at $40.61. The total traded volume of the day was 1,301,426 shares.

In an insider trading activity, The officer (VP of Finance & Administration), of Tesaro, Inc., English Edward C had unloaded 7,000 shares at $41.21 per share in a transaction on June 10, 2016. The total value of transaction was $288,470. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.